ViroPharma Inc., of Exton, Pa., said the European Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of a pediatric use marketing authorization application for Buccolam (midazolam, oromucosal solution) for treating prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents.